SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing significant volatility and high trading volume as investors focus on imminent clinical catalysts, including the REGAL trial's 80th event and potential acquisition interest. Community sentiment is deeply polarized, with bullish long-term investors dismissing early morning price dips as orchestrated stop-loss raids by short sellers, while vocal skeptics warn of a potential sell-off.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is attracting intense investor attention following a major pivot toward providing power infrastructure for AI data centers, which has triggered aggressive short-covering and bullish sentiment. The community is actively debating the stock's transition from a residential solar play to a broader data-center technology provider, while closely monitoring key resistance levels and insider activity.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is surging following a strong quarterly earnings report that featured record revenue and a significant backlog, sparking intense community debate over whether this represents a sustainable turnaround or a short-term squeeze. Investors are actively contrasting these strong top-line metrics against concerns over forward guidance and legal developments, while the stock continues to be a focal point for those monitoring the broader expansion of autonomous drone and defense technology spending.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group Inc. is seeing intense activity driven by a potential short squeeze, fueled by elevated short interest, high borrow fees, and an increasing focus on long-term growth catalysts like the Uber and Nuro robotaxi partnership. The community is sharply divided, with bulls pointing to the squeeze potential and institutional backing while bears emphasize ongoing dilution concerns, production cuts, and significant workforce reductions.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors react to the official initiation of a global Phase 3 trial for its lung cancer candidate, a milestone that signals significant progress toward commercial readiness. The community is actively discussing the companys pipeline potential, the strategic hire of a new Chief Commercial Officer, and the possibility of a major buyout by a large pharmaceutical entity.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is seeing heightened social media conversation driven by intense community debate over its depressed valuation relative to $2 billion in annual sales and potential buyout speculation. While some investors are bullish on a potential short squeeze given the significant short float and upcoming pipeline catalysts, others are expressing frustration over the lack of management communication and persistent price stagnation.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack in the Box is trending as retail traders target the stock for a potential short squeeze, citing its relatively small float and high short interest compared to other restaurant peers. Community sentiment remains divided between those betting on a turnaround following recent index reconstitutions and others expressing skepticism regarding the company's long-term debt and market positioning.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is trending as it hits new record highs, fueled by intense institutional accumulation and its critical role in wiring high-speed connectivity for AI data center clusters. Community members are actively debating the stock's parabolic move and valuation, with many focused on its inclusion in the Nasdaq-100 and the company's status as a foundational player in the AI infrastructure buildout.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as shareholders react to a significant selloff following management's commentary on slowing growth for its Watchman franchise, sparking intense community debate over whether this represents a long-term value opportunity or a deeper structural decline. While many investors are actively accumulating shares and positioning for a potential rebound fueled by existing share repurchase programs and solid long-term fundamentals, others remain concerned about mounting technical weakness and the broader rotation of capital into more high-momentum AI sectors.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is garnering significant attention as investors react to its recent inclusion in the Russell index and ongoing community speculation regarding a potential short squeeze driven by high short interest. Market discourse is largely fueled by the broader drone and autonomous defense sector's growth, with bulls pointing to the company's strategic partnerships and government interest as key long-term catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NAMS Here I have shown that year 1-2 placebo event rate is strongly predicted by year 0-1 event rate in recent LLT CVOTs. I imagine management will provide a similar (but better) analysis along with the year 1-2 event rate for PREVAIL during investor day in August. This could potentially give a strong signal of efficacy if the blended (blinded) event rate falls well below the linear regression line. Look for a year 1-2 event rate below 3.5.

Hospital.physician

StockTwits For Android 

NewAmsterdam Pharma Company NV

 Here I have shown that year 1-2 placebo event rate is strongly predicted by year 0-1 event rate in recent LLT CVOTs. I imagine management will provide a similar (but better) analysis along with the year 1-2 event rate for PREVAIL during investor day in August. This could potentially give a strong signal of efficacy if the blended (blinded) event rate falls well below the linear regression line. Look for a year 1-2 event rate below 3.5.